Momanose (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors inside nasal mucosal cells. This binding modifies gene expression, leading to reduced production of inflammatory cytokines and chemokines. The result is decreased swelling, mucus formation, and immune‑cell infiltration, which alleviates nasal inflammation.

The specific dose and frequency of Momanose are determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms, and clinical response. Patients should follow the prescriber’s instructions and the product label without deviation.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. The prescriber should weigh the potential benefits against any possible risks. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their healthcare provider.

To request Momanose, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Momanose (mometasone furoate) is a high‑potency intranasal glucocorticoid with a low systemic absorption profile, similar to other modern nasal steroids such as fluticasone propionate. Compared with older agents, it often provides effective symptom control with a comparable safety margin when used as directed.

Store Momanose at room temperature, below 25 °C (77 °F). Keep the spray in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed when not in use.

Momanose is a nasal spray. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and spray the prescribed number of sprays while breathing in gently. The process is repeated in the other nostril if directed by the prescriber.

Serious but rare risks include nasal septal perforation, severe allergic reactions (anaphylaxis), adrenal suppression with prolonged high‑dose use, and opportunistic infections of the nasal mucosa. Any signs of these events should prompt immediate medical evaluation.

Momanose should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. Patients with active untreated fungal, viral or bacterial infections of the nasal passages should not use the spray until the infection is resolved.